SG Americas Securities LLC Sells 24,197 Shares of STAAR Surgical (NASDAQ:STAA)

SG Americas Securities LLC trimmed its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 62.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,454 shares of the medical instruments supplier's stock after selling 24,197 shares during the period. SG Americas Securities LLC's holdings in STAAR Surgical were worth $451,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in STAA. Raymond James & Associates boosted its position in shares of STAAR Surgical by 96.4% during the first quarter. Raymond James & Associates now owns 12,704 shares of the medical instruments supplier's stock worth $1,015,000 after buying an additional 6,234 shares during the period. US Bancorp DE boosted its position in shares of STAAR Surgical by 23.5% during the first quarter. US Bancorp DE now owns 2,735 shares of the medical instruments supplier's stock worth $219,000 after buying an additional 520 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of STAAR Surgical by 18.6% during the first quarter. PNC Financial Services Group Inc. now owns 1,287 shares of the medical instruments supplier's stock worth $102,000 after buying an additional 202 shares during the period. Rhumbline Advisers boosted its position in shares of STAAR Surgical by 2.2% during the first quarter. Rhumbline Advisers now owns 139,573 shares of the medical instruments supplier's stock worth $11,153,000 after buying an additional 3,005 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of STAAR Surgical by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,445 shares of the medical instruments supplier's stock worth $1,394,000 after buying an additional 1,663 shares during the period. 96.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 4,042 shares of the company's stock in a transaction on Monday, January 8th. The shares were purchased at an average price of $27.11 per share, for a total transaction of $109,578.62. Following the completion of the purchase, the insider now directly owns 10,768,430 shares of the company's stock, valued at $291,932,137.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, major shareholder Broadwood Partners, L.P. bought 4,042 shares of the firm's stock in a transaction dated Monday, January 8th. The shares were bought at an average price of $27.11 per share, with a total value of $109,578.62. Following the completion of the transaction, the insider now owns 10,768,430 shares of the company's stock, valued at $291,932,137.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Aimee S. Weisner bought 1,750 shares of the firm's stock in a transaction dated Thursday, March 14th. The stock was purchased at an average cost of $38.11 per share, for a total transaction of $66,692.50. Following the transaction, the director now directly owns 10,864 shares of the company's stock, valued at approximately $414,027.04. The disclosure for this purchase can be found here. Corporate insiders own 1.10% of the company's stock.

STAAR Surgical Trading Up 7.0 %

NASDAQ:STAA traded up $3.17 on Friday, hitting $48.68. The company's stock had a trading volume of 1,864,355 shares, compared to its average volume of 757,157. The stock has a fifty day moving average of $34.32 and a two-hundred day moving average of $34.76. The firm has a market capitalization of $2.38 billion, a P/E ratio of 113.21 and a beta of 0.86. STAAR Surgical has a one year low of $26.66 and a one year high of $73.13.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). The business had revenue of $76.27 million during the quarter, compared to the consensus estimate of $75.94 million. STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. STAAR Surgical's quarterly revenue was up 19.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.04 EPS. As a group, sell-side analysts anticipate that STAAR Surgical will post 0.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a research report on Thursday. William Blair raised STAAR Surgical from a "market perform" rating to an "outperform" rating in a research report on Thursday. Piper Sandler reduced their price objective on STAAR Surgical from $40.00 to $33.00 and set a "neutral" rating for the company in a research report on Tuesday, February 27th. Stifel Nicolaus reiterated a "buy" rating and set a $50.00 target price on shares of STAAR Surgical in a report on Monday, April 1st. Finally, Mizuho dropped their target price on STAAR Surgical from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $45.63.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.